EP1453516A2 - Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament - Google Patents

Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament

Info

Publication number
EP1453516A2
EP1453516A2 EP02772368A EP02772368A EP1453516A2 EP 1453516 A2 EP1453516 A2 EP 1453516A2 EP 02772368 A EP02772368 A EP 02772368A EP 02772368 A EP02772368 A EP 02772368A EP 1453516 A2 EP1453516 A2 EP 1453516A2
Authority
EP
European Patent Office
Prior art keywords
group
alkyl
substituted
optionally substituted
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02772368A
Other languages
German (de)
English (en)
Inventor
Frank Himmelsbach
Klaus Fuchs
Hans Briem
Katja Fechteler
Markus Kostka
Cornelia Dorner-Ciossek
Klaus Bornemann
Klaus Klinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1453516A2 publication Critical patent/EP1453516A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to trisubstituted pyrimidines of the formula (I),
  • Amyloid precursor protein amyloid precursor protein
  • Engl amyloid precursor protein
  • the ⁇ -secretase cleaves within the Aß region of the APP and thus leads to the secretion of the soluble N-terminal region of the
  • Aß Proteins ( ⁇ -APPs) and after the ⁇ -secretase cut to release p3.
  • ⁇ -APPs proteins
  • the amyloidogenic pathway leads to the formation of Aß in that two proteases generate the N-terminus (ß-secretase) and the C-terminus ( ⁇ -secretase) of Aß.
  • Aß can be detected in vivo in human plasma and cerebrospinal fluid.
  • Aß can also be secreted in cell culture in the cell culture supernatant in different cell types are detected which endogenously express or overexpress APP or fragments thereof.
  • the present invention is based on the further object of providing compounds which can be used effectively for the prevention or treatment of Alzheimer's disease.
  • the compounds according to the invention are trisubstituted pyrimidines of the formula (I)
  • R a is a hydrogen atom or an alkyl group
  • Rb is a phenyl group substituted by the radicals Ri to R5, where Rj is a hydrogen, fluorine, chlorine, bromine or iodine atom, a Ci .g-alkyl, hydroxyl or Ci_6-alkoxy group, a C3_7-cycloalkyl, C4_7-cycloalkoxy or (C3_7-cycloalkyl) alkyl group, which in the cycloalkyl part can each be substituted by one or two alkyl groups, a C2_5-alkenyl, C3_5-alkenyloxy, C2_5-alkynyl or C3_5-alkynyloxy group, in which the vinyl and ethynyl part cannot be linked to an oxygen atom.
  • W is an oxygen or sulfur atom, a sulfinyl, sulfonyl, imino, N-alkylimino, N-formylimino, N-alkylcarbonylimino, N-cyano-imino,
  • N-alkoxycarbonyl-imino or N-alkylsulfonyl-imino group a formylamino, N-alkyl-formylamino, alkylcarbonylamino, N-alkyl-alkylcarbonylamino, alkylsulfonylamino or N-alkyl-alkylsulfonylamino group, an alkylcarbonyl, carboxy , Alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or cyano group, an aminosulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl group, an alkyl or alkoxy group substituted by R9, in which
  • R9 is a hydroxyl, alkoxy, amino, alkylamino, dialkylamino, alkylsulfenyl,
  • N-alkyl-cyanamino group means R2 and R3 each independently of one another hydrogen, fluorine, chlorine, bromine or iodine atoms, alkyl, alkoxy, fluoroalkyl, fluoroalkoxy or cyano groups or R2 together with 3, if these are adjacent Carbon atoms are bonded, also one optionally substituted by one or two alkyl groups
  • Methylenedioxy group an n-C3_6-alkylene group optionally substituted by one or two alkyl groups, in which a methylene group can be replaced by the radical W, where W has the meanings mentioned for W and additionally represents a trifluoroacetylimino group, one optionally substituted by a fluorine, Chlorine, bromine or iodine atom, by an alkyl, trifluoromethyl,
  • R4 and R5 each independently of one another are hydrogen, fluorine or chlorine atoms or R4 together with R a , provided that R4 is in the o-position to that substituted by R a
  • Nitrogen atom also represent an n-C2_4-alkylene group which is optionally substituted by one or two alkyl groups, an C 1 -C 4 -alkyl group which is optionally mono- or polysubstituted by R9, where R9 is defined as mentioned above, one by a fluoromethyl, chloromethyl , Bromomethyl, difluoromethyl or
  • Trifluoromethyl group substituted methyl group a C3_7-cycloalkyl, (C3_7-cycloalkyl) alkyl or arylalkyl group, a C3_5 alkenyl or C3_5 alkynyl group in which the vinyl and ethynyl part cannot be linked to the nitrogen atom of the R ⁇ NRd group, Rd a hydrogen atom or an alkyl group, or R c together with R (j and the one with them connected nitrogen atom is a 3- to 7-membered alkyleneimino group or a 6- or 7-membered alkyleneimino group in which a methylene group in the 4-position is replaced by the radical W, where W is as defined above and R e is a nitro, Amino, alkylamino, dialkylamino or azido group, a 4- to 7-membered alkyleneimino group optionally substituted by one or two alkyl groups, in which one
  • Methylene groups can be replaced by a carbonyl group, in which case in this alkyleneimino group a CH2 group in the 4-position can be replaced by the radical W, where W is as defined above, a formylamino, N-alkylformylamino, alkylcarbonylamino, N-alkyl-alkylcarbonylamino-, di (alkylcarbonyl) amino-, (C3_7-cycloalkyl) carbonylamino-, N-alkyl- (C ' 3_7-cycloalkyl) carbonylamino-, (C3_7-cycloalkyl) alkylcarbonylamino-, N-alkyl- (C3 _7-cycloalkyl) alkylcarbonylamino-, arylcarbonylamino-, N-alkyl-arylcarbonylamino-, arylalkylcarbonylamino-, N-alkyl-arylcarbonylamino
  • (C5_7-cycloalkyl) alkylcarbonylamino group in which the cycloalkyl parts can each be substituted by one or two alkyl groups and additionally a methylene group in the cycloalkyl parts of the above-mentioned groups is replaced by the radical W, where W is defined as mentioned above, a C2-5 -Alkenylcarbonylamino-, N-alkyl-C2_5-alkenylcarbonylamino-,
  • Perfluoroalkylsulfonylamino or N-alkyl-perfluoroalkylsulfonylamino group one optionally substituted in the alkyleneimino part by one or two alkyl groups
  • Alkyleneimino part is in each case 4 to 7-membered, one optionally substituted in the alkyleneimino part by one or two alkyl groups
  • Alkyleneimino part is in each case 6- or 7-membered and in each case one methylene group in the 4-position of the alkyleneimino part is replaced by the radical W, W being defined as mentioned above, one optionally substituted in the alkyleneimino part by one or two alkyl groups
  • Alkyleniminothiocarbonylamino- or N-alkylalkyl iminothiocarbonylamino group where the alkylene imino part is in each case 4 to 7-membered, one optionally substituted in the alkylene imino part by one or two alkyl groups
  • Rg is a hydrogen atom or an alkyl group
  • R7 and Rg each independently of one another are hydrogen atoms or alkyl groups optionally substituted by R9, or
  • Rö and R7 together form an n-C2-3 alkylene group and in hydrogen atom or an alkyl group optionally substituted by R9, where R9 is defined as mentioned above, an imidazolidin-2,4-dione-1-yl- or jidazolidin-2,4-dione-3- optionally substituted by 1 to 3 alkyl groups yl group, where one of the alkyl groups can be substituted by R9, a 1,3-dihydro-imidazol-2-one-l-yl group optionally substituted by 1 to 3 alkyl groups, where one of the alkyl groups can be substituted by R9, a 2,4-dihydro-l, 2,4-triazol-3-one-2-yl- or 2,4-dihydro-l, 2,4-triazol-3-one-4 optionally substituted by 1 or 2 alkyl groups -yl group, where one of the alkyl groups can be substituted by R9, a Ri4 Ri5) -
  • Ri 3 is a hydrogen atom, an alkyl- or C3_7-cycloalkyl group, Ri 4 and R15 each independently of one another an alkyl group, or R14 and Ri 5 together with the nitrogen atom in between is a 4- bis optionally substituted by one or two alkyl groups
  • Trichloromethyl group, Ri 7 and Rig which may be the same or different, each have a hydrogen atom or an alkyl group or
  • Rj6 and Rjg together represent an n-C3_5-alkylene group optionally substituted by one or two alkyl groups and Rl7 represents a hydrogen atom or an alkyl group or Ri 7 and Rjg together represent an n-C2_4-alkylene group optionally substituted by one or two alkyl groups and
  • Ri 6 represents a hydrogen atom, an alkyl or C3_7 cycloalkyl group, a (R 19 R 2 () PO) -NH group optionally substituted on the nitrogen atom by an alkyl group, in which R ⁇ g and R20, which may be the same or different, represent alkyl or aryl groups, an alkyl or alkoxy group substituted by R9, in which R9 is as defined above, a formyl, alkylcarbonyl, l- (hydroxyimino) alkyl -, l- (alkoxyimino) alkyl, carboxy,
  • Rjo an d R 1 together represent an optionally substituted by one or two alkyl groups
  • n-C2_4-alkylene group represent a optionally substituted by one to three alkyl groups, or a substituted amidino group by a hydroxy, alkoxy, cyano, alkoxycarbonyl or arylalkoxycarbonyl amidino group, those on the nitrogen atoms additionally by one or two
  • Alkyl groups can be substituted, mean their tautomers, their stereoisomers or their physiologically tolerable salts, where, unless stated otherwise, one of the aryl parts mentioned in the definition of the abovementioned radicals
  • Phenyl group is to be understood, which is in each case monosubstituted by R21, mono-, di- or tri-substituted by R22 or monosubstituted by R21 and additionally mono- or disubstituted by R22, where the substituents can be identical or different, and 21 a cyano, carboxy, aminocarbonyl, alkylamino carbonyl,
  • Phenylsulfonylamino N-alkyl-alkylcarbonylamino, N-alkyl-phenylalkylcarbonylamino, N-alkyl-phenylcarbonylamino, N-alkyl-alkylsulfonylamino, N-alkyl-phenylalkylsulfonylamino, N-alkyl-phenylsulfonylamino, amino sulfonyl, alkylamino sulfonyl, dialkylamino sulfonyl, pyrrolidino. Piperidino, Morpholino, Piperazino or
  • 4-alkyl-piperazino group and R22 represent an alkyl, hydroxy or alkoxy group, a fluorine, chlorine, bromine or iodine atom, where two radicals R22, if these are bonded to neighboring coblene atoms, also an alkylene group with 3 to 6 carbon atoms, can represent a 1,3-butadiene-l, 4-diylene group or a methylenedioxy group, among the heteroaryl parts a 5-membered heteroaromatic ring with an imino group, an oxygen or sulfur atom or a 5-membered heteroaromatic ring with an oxygen or Sulfur atom and one to two nitrogen atoms or a 5-membered heteroaromatic ring with an imino group and one to three nitrogen atoms or a 6-membered heteroaromatic ring with one to three nitrogen atoms is to be understood, the above-mentioned 5- and 6-membered heteroaromatic rings being understood by one or two alky
  • Preferred compounds of the general formula (I) are those in which R a is a hydrogen atom or an alkyl group, Rb is a phenyl group substituted by the radicals R j to R5, where Rl is a hydrogen, fluorine, chlorine, bromine or iodine atom, a C ⁇ _6 Alkyl, hydroxyl or Cj.g-alkoxy group, a C3_6-cycloalkyl, Cs.g-cycloalkoxy or (C3_6-cycloalkyl) alkyl group, which in the cycloalkyl part can each be substituted by one or two alkyl groups, a C2_5-alkenyl, C3_5-alkenyloxy, C2-5-alkynyl or C3_5-alkynyloxy group, in which the vinyl and ethynyl part cannot be linked to an oxygen atom, an aryl, aryloxy, arylalkyl, aryl
  • W is an oxygen or sulfur atom, a sulfinyl, sulfonyl, imino, N-alkylimino, N-formylimino, N-alkylcarbonylimino, N-cyanoimino, N-alkoxycarbonylimino - or N-alkylsulfonyl-imino group, a formylamino, N-alkyl-formylamino, alkylcarbonylamino, K-alkyl-alkylcarbonylamino, alkylsulfonylamino or N-alkyl-alkylsulfonylamino group, an alkylcarbonyl, carboxy, alkoxycarbonyl, aminocarbonyl -, Alkylaminocarbonyl, dialkylaminocarbonyl or cyano group, an amino sulfonyl, alkylamino sulfonyl or dialkylaminosulfonyl group,
  • Alkyleneimino group in which a methylene group in the 4-position is replaced by the radical W where W is defined as mentioned above, a formylamino-, N-alkyl-formylamino-, alkylcarbonylamino-, N-alkyl-alkylcarbonylamino-, alkylsulfonylamino-, N-alkyl-alkylsulfonylamino-, perfluoroallcylsulfonylamino-, N-alkyl-perfluoroalkylsulfonylaniino-, alkoxycarbonylalkylaminooxy-, N-alkyl Represents cyanamino or N-alkyl-cy-anamino group,
  • R2 and R3 each independently of one another are hydrogen, fluorine, chlorine, bromine or iodine atoms, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy or cyano groups or R2 together with R3, provided these are attached to adjacent carbon atoms are bound, also one optionally substituted by one or two alkyl groups
  • Methylenedioxy group an n-C3_6-alkylene group optionally substituted by one or two alkyl groups, in which a methylene group can be replaced by the radical W, where W has the meanings mentioned for W and additionally represents a trifluoroacetylimino group, one optionally substituted by a fluorine, Chlorine, bromine or iodine atom, by an alkyl, trifluoromethyl, hydroxy,
  • Alkoxy, trifluoromethoxy or cyano group substituted 1,3-butadiene-1,4-diylene group, the above-mentioned 1,3-butadiene-1,4-diylene groups additionally by a fluorine or chlorine atom, by an alkyl, trifluoromethyl or alkoxy group may be substituted
  • R c is a Ci.g-alkyl group which is substituted by one or more hydroxyl, alkoxy
  • Dialkylamino group can be substituted, Rd a hydrogen atom or a C ⁇ .
  • Alkyl group, and R e is a nitro, amino, alkylamino, dialkylamino or azido group, a 5- to 7-membered alkyleneimino group optionally substituted by one or two alkyl groups, a 5- to 7- optionally substituted by one or two alkyl groups membered alkyleneimino group in which one or two methylene groups adjacent to the nitrogen atom can be replaced by a carbonyl group, and in the alkyleneimino group additionally a methylene group in the 4-position to the imino nitrogen atom can be replaced by the radical W, where W is as defined above, a formylamino, N-alkyl-formylamino, alkylcarbonylamino, N-alkylalkylcarbonylamino, di (alkylcarbonyl) amino, (C3.7-cycloalkyl) carbon
  • alkyleneiminocarbonylamino group where the alkyleneimino part is in each case 6- or 7-membered and in each case one methylene group in the 4-position of the alkyleneimino part is replaced by the radical W, where W is defined as mentioned above, an alkyleneiminothiocarbonylamino optionally substituted in the alkyleneimino part by one or two alkyl groups.
  • alkyleneimino part is in each case 4- to 7-membered, an alkyleneiminothiocarbonylamino or N-alkylalkyleneiminothiocarbonylamino group which is optionally substituted in the alkyleneimino part by one or two alkyl groups, the alkyleneimino part in each case being 6- or
  • R ⁇ is a hydrogen atom or an alkyl group
  • Rg which may be the same or different, are hydrogen atoms or alkyl groups optionally substituted by R9 or Rg and R7 together represent an n-C2_3-alkylene group
  • Rg represents a hydrogen atom or an alkyl group optionally substituted by R9, R9 as mentioned above and XO or S denotes an imidazolidin-2,4-dione-1-yl or imidazolidine-2,4-dione-3-yl group which is optionally substituted by an alkyl group
  • Ri 3 is a hydrogen atom, an alkyl or C3_7 cycloalkyl group, R j 4 and R15, which may be the same or different, each one
  • R14 and R15 together with the intermediate nitrogen atom represent a 4- to 7-membered alkyleneimino group which is optionally substituted by one or two alkyl groups or a 6- or 7-membered alkyleneimino group which is optionally substituted by one or two alkyl groups, in which one
  • Methylene group in the 4-position is replaced by the radical W, where W is defined as mentioned above and R13 represents a hydrogen atom, an alkyl or C3_7-cycloalkyl group, l6 represents a hydrogen atom, an alkyl, C3 “7-cycloalkyl, trifluoromethyl or trichloromethyl group,
  • Ri 7 and R ⁇ g each independently represent a hydrogen atom or an alkyl group, or
  • Ri 6 and Ri g together form an n-C3_5-alkylene group optionally substituted by one or two alkyl groups, and
  • R j 7 represents a hydrogen atom or an alkyl group
  • R 1 and R j g together form an n-C2-4-alkylene group optionally substituted by one or two alkyl groups, and
  • R represents a hydrogen atom, an alkyl or C3_7-cycloalkyl group, an (R 19 R2oPO) -NH group optionally substituted on the nitrogen atom by an alkyl group, in which
  • Ri 9 and R20 represent alkyl groups, an R9-substituted alkyl or alkoxy group in which R9 is as defined above, a formyl, alkylcarbonyl, l- (hydroxyimino) alkyl, l- ( Alkoxyimino) alkyl, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or cyano group, a sulfo, alkoxysulfonyl, aminosulfonyl, alkylaminosulfonyl or
  • N-alkyl-alkylsulfonylamino group an alkylcarbonyl, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or cyano group, an aminosulfonyl, alkylaminosulfonyl or dialkylamino sulfonyl group, an alkyl or alkoxy group substituted by R9, where
  • R9 is a hydroxy, C 1 - alkoxy, amino, C 1 _2 ⁇ alkylamino, di (C ⁇ _2-alkyl) - amino, carboxy, C ⁇ _2- alkoxycarbonyl, aminocarbonyl, Ci _2-alkylaminocarbonyl -, Di- (C ⁇ _2-alkyl) -aminocarbonyl ⁇ or cyano group, a 4- to 6-membered alkyleneimino group, a morpholino, piperazino or 4-methylpiperazino group, an alkylcarbonylamino, N-methylalkylcarbonylamino, alkylsulfonylamino Represents N-methyl-alkylsulfonylamino, alkoxycarbonylamino or N-methylalkoxycarbonylamino group, R2 is a hydrogen, fluorine, chlorine or bromine atom, a methyl, methoxy,
  • R3 is a hydrogen, fluorine or chlorine atom, or
  • R c is a methyl, ethyl or propyl group which is substituted by a hydroxyl, alkoxy,
  • Dialkylamino group can be substituted, Rd is a hydrogen atom or a methyl group, and R e is a nitro, amino, alkylamino or dialkylamino group, a pyrrolidino, piperidino, morpholino, piperazino, 4-methylpiperazino, 2-oxo - pyrrolidino, 2-oxopiperidino, 2,5-dioxopyrrolidino or 2,6-dioxopiperidino group, a formylamino, N-alkylformylamino, alkylcarbonylamino, N-alkylalkylcarbonylamino, C3_6 -Cycloalkylcarbonylamino-, N-alkyl- C3_6-cycloalkylcarbonylamino-, (C3_6-cycloalkyl) alkylcarbonylamino-, N-alkyl-
  • Trifluoromethylsulfonylamino or alkyl trifluoromethylsulfonylamino group an alkylcarbonylamino or alkylalkylcarbonylamino group, the alkyl part of the alkylcarbonyl group in each case being substituted by the radical R9, where R9 is defined as mentioned above, a pyrrolidinocarbonylamino, piperidinocarbonylamino, homopiperidinocarbonylamino, morpholinocarbonylamino,
  • Morpholinothiocarbonylamino, piperazinothiocarbonylamino or 4-alkylpiperazinothiocarbonylamino group each of which may be substituted on the thiocarbonylamino part by an alkyl group, an R7NR8-CO-NR6 or R7NR8-S ⁇ 2-NR6 group in which R, a hydrogen atom or an alkyl group
  • R7 and Rg each independently of one another are hydrogen atoms or alkyl groups optionally substituted by R9, or Rö and R7 together form an n-C2-3-alkyl group, and
  • Rg represents a hydrogen atom or an alkyl group which is optionally substituted by R9, where R9 is defined as mentioned above, an imidazolidin-2,4-dione-l-yl or which is optionally substituted by an alkyl group
  • R ⁇ 3 is a hydrogen atom or an alkyl group
  • R ⁇ 4 and Ri 5 are each independently an alkyl group or
  • Ri 4 and Ri 5 together with the nitrogen atom in between represent a pyrrolidino, piperidino, morpholino, piperazino or 4-alkylpiperazino group
  • R ⁇ ß is an alkyl or trichloromethyl group
  • R17 represents a hydrogen atom or an alkyl group and R ⁇ g represents a hydrogen atom, a dialkylphosphinylamino group optionally substituted on the nitrogen atom by an alkyl group in which the alkyl substituents can be the same or different, a carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or cyano group, an aminosulfonyl, alkylaminosulfonyl or dialkylaminylsulfonyl group, , Piperidinocarbonyl, morpholinocarbonyl, piperazinocarbonyl, 4-alkyl-piperazinocarbonyl, pyrrolidinosulfonyl, piperidinosulfonyl, morpholinosulfonyl, piperazinosulfonyl or 4-alkylpiperazinosulfonyl group, optionally substituted by a methyl group,
  • RlO and dl 1 together represent an n-C2_3-alkylene group optionally substituted by one or two methyl groups, an amidino group optionally substituted by one to three alkyl groups or an amidino group substituted by a hydroxyl, alkoxy, cyano, alkoxycarbonyl or phenylalkoxycarbonyl group, the on the nitrogen atoms can additionally be substituted by one or two methyl groups, where, unless stated otherwise, the phenyl groups mentioned in the definition of the abovementioned radicals are each a fluorine, chlorine or bromine atom, by a methyl or methoxy - Or trifluoromethyl group may be substituted, and, unless stated otherwise, the alkyl, alkylene and alkoxy parts mentioned above each contain 1 to 4 carbon atoms, their tautomers, their stereoisomers and their salts.
  • R a is a hydrogen atom or a methyl group
  • R Q is a phenyl group substituted by the radicals R ⁇ to R5, where j is a hydrogen, fluorine, Clilor, bromine or iodine atom, a C 1.4 alkyl, hydroxy or C 1.4 alkoxy group, an ethynyl, phenyl, phenyloxy or benzyloxy group, a methylsulfenyl, methylsulfmyl or Methylsulfonyl group, a trifluoromethyl, trifluoromethoxy or 1,1,2,2-tetrafluoroethoxy group, a nitro, dimethylamino or azido group, a morpholino group, an acetylamino or methylsulfonylamino group, an acetyl, carboxy, C ⁇ _2 alkoxycarbonyl - or cyano group, an aminosulfonyl
  • Ci _4-alkoxycarbonylamino group is substituted, R2 represents a hydrogen, fluorine or chlorine atom or a methyl group, R3 represents a hydrogen, fluorine or chlorine atom or
  • R2 together with R3, provided that these are bonded to adjacent carbon atoms, also an n-C3_4-alkylene group, a -CH2CH2NHCH2CH2 group which is optionally substituted on the nitrogen atom by a methyl or trifluoroacetyl group or a 1,3-butadiene-1,4-diylene group,
  • R4 and R5 each independently represent hydrogen or fluorine atoms
  • R c is a methyl, ethyl or propyl group which can be terminally substituted by a hydroxyl, methoxy or dimethylamino group,
  • R is a hydrogen atom or a methyl group
  • R e is a nitro or aniino group, a formylamino, C 1.4- alkylcarbonylamino, cyclopropylcarbonylamino, phenylcarbonylamino, C ⁇ _3-alkoxycarbonylamino, benzyloxycarbonylamino, phenyloxycarbonylaniino, C 1.4- alkylsulfonylamino methyl-methylsulfonylamino,
  • C 1-3 -alkyl groups where the alkyl groups can be substituted by a hydroxy, methoxy, dimethylamino or C ⁇ _2-alkoxycarbonyl group, or Rg and R7 together represent an n-C2_3-alkylene group, and Rg represents a hydrogen atom or a methyl group, an imidazolidine-2,4-dione-3 -yl group, a carboxy, C _2-alkoxycarbonyl or cyano group, an aminosulfonyl, methylamino sulfonyl or dimethylaminosulfonyl group, a 1-pyrrolyl or 5-tetrazolyl group mean their tautomers , their stereoisomers and their salts.
  • R a and independently of one another a hydrogen atom or a methyl group, R ⁇ is a phenyl group substituted by one or two fluorine or chlorine atoms,
  • R c is a methyl, ethyl or propyl group which may be substituted at the end by a dimethylamino group, the tautomers, the stereoisomers and the salts thereof.
  • R e represents a nitro-acetylamino, trifluoroacetylamino, methylsufonamino or amino group, or a urea radical of the formula
  • Rg is a hydrogen atom or an alkyl group, and Rg, which may be the same or different, hydrogen atoms or alkyl groups optionally substituted by hydroxyl, methoxy or dimethylamino, or Rg and R7 together form an n-C2_3-alkylene group, and
  • Rg is a hydrogen atom or one optionally by hydroxy, methoxy or
  • R7 and Rg taken together represent a C4_g alkylenediyl group, where one or two non-adjacent CH 2 groups can be replaced by -O-, -S- or -NR23-, where R23 is a hydrogen atom, a C 1.3 alkyl group or
  • 2- (4-chloroanuino) -4-methylamino-5-nitro-pyrimidine gives 2- (3,4-DicMorarühno) -4-methylamino-5-amino -pyrimidine 2- (3,4-DicMoranil o) -4-methylamino-5-methylsulfonamino-pyrimidine 2- (3,4-dichloroanilino) -4- (3-dimethylan ⁇ inopropyl) -amino-5-nitro-pyrimidine 2- ( 3,4-dichloroanilino) -4-methylamino-5-acetamido-pyrimidine 2- (3,4-DicWoranilino) -4-methylamino-5- (-methyl-N-methylsulfonylamino) pyrimidine 2- (3,4-DicWoranilino ) -4-methylamino-5- (2-oxo-
  • the invention relates to the respective compounds, optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, in the form of the tautomers and in the form of the free bases or the corresponding ones
  • Acid addition salts with pharmacologically acceptable acids - such as acid addition salts with hydrohalic acids - for example hydrochloric or hydrobromic acid - or organic acids - such as oxalic, fumaric, diglycolic or methanesulfonic acid.
  • branched and unbranched alkyl groups with ibis 4 are considered as alkyl groups (also insofar as they are part of other radicals). Examples include: methyl, ethyl, propyl and butyl. Unless otherwise stated, are from the above-mentioned terms propyl and butyl include all of the possible isomeric forms. Accordingly, the term propyl includes the two isomeric radicals n-propyl and iso-propyl and the term butyl n-butyl, iso-butyl, sec. Butyl and tert-butyl. If necessary, common abbreviations such as Me for methyl, Et for ethyl etc. are used to denote the alkyl radicals mentioned above.
  • Branched and unbranched alkylene bridges with 1 to 4 are considered as alkylene groups.
  • alkylene groups For example, the following are mentioned: methylene, ethylene, propylene and butylene Unless otherwise stated, the abovementioned names propylene and butylene encompass all of the possible isomeric forms. Accordingly, the term propylene comprises the two isomeric bridges n-propylene and dimethylmethylene and the term butylene the isomeric bridges n-butylene, 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene and 1,2-dimethylethylene.
  • alkenyl groups also insofar as they are part of other radicals
  • branched and unbranched alkenyl groups with 2 to 4 carbon atoms are mentioned, provided that they have at least one double bond, such as vinyl (if no inconsistent enamines or enol ethers are formed), propenyl, isopropenyl and butenyl.
  • Halogen is generally referred to as fluorine, chlorine, bromine or iodine. Unless otherwise stated, chlorine is considered preferred in the context of the present invention.
  • Another aspect of the present invention aims at the use of the compounds of formula (I) defined above as medicaments.
  • the present invention aims at the use of the compounds of formula (I) for the manufacture of a medicament for the prevention and / or treatment of diseases in which by intervention (preferably inhibition) in the process of Aß formation or release from cells, a therapeutic Benefit can be achieved.
  • preference is given to the use of compounds of the formula (I) mentioned above for the preparation of a medicament for the prevention and / or treatment of Alzheimer's disease.
  • the present invention thus furthermore relates to medicaments comprising at least one compound of the formula I above, their tautomers, their stereoisomers or their physiologically tolerable salts, their use for the treatment of diseases in which the proliferation of cells, in particular that of endothelial cells, plays a role plays, and process for their production,.
  • Synthetic access to the compounds of the formula (I) according to the invention can be carried out using different methods, possibly based on or using conventional chemical synthesis methods, as described in more detail below.
  • the compounds of formula (I) are prepared by: a. a compound of the formula
  • R c to R e are as defined in claims 1 to 8 and Z represents a leaving group with an amine of the formula
  • the reaction is advantageously carried out in a solvent such as ethanol, isopropanol, butanol, tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethyl sulfoxide, ethylene glycol monomethyl ether, ethylene glycol diethyl ether or sulfolane, optionally in the presence of an inorganic base, for example sodium carbonate or potassium hydroxide, or a tertiary organic base, for example Triethylamine, N-ethyl-diisopropylamine or pyridine, the latter also serving as solvents at the same time, and optionally in the presence of a reaction accelerator such as a copper salt, a corresponding amine hydrohalide or alkali halide at temperatures between 0 and 250 ° C, but preferably at temperatures between 20 and 200 ° C, carried out.
  • a reaction accelerator such as a copper salt, a corresponding amine hydrohalide or
  • R ⁇ , R j and R e as defined in claims 1 to 8, and Z2 represents a leaving group, with an amine of the formula
  • the reaction is advantageously carried out in a solvent such as ethanol, isopropanol, butanol, tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethyl sulfoxide, ethylene glycol monomethyl ether, ethylene glycol diethyl ether or sulfolane, optionally in the presence of an inorganic base, for example sodium carbonate or potassium hydroxide, or a tertiary organic base, for example Triethylamine, N-ethyl-diisopropylamine or pyridine, the latter at the same time also serving as a solvent, and optionally in the presence of a reaction accelerator such as a copper salt, a corresponding amine hydrohalide or alkali halide at temperatures between 0 and 250 ° C., but preferably at Temperatures between 20 and 200 ° C, carried out.
  • a solvent such as ethanol, isopropanol, butan
  • reaction can also be carried out without a solvent or in an excess of the compound of the general formula V used.
  • a compound of the formula I in which R e represents an amino group a compound of the formula I in which R e represents a nitro group, and optionally a compound of the formula I thus obtained according to the invention having a free amino or imino group, by Implementation with an electrophile selected from the
  • the subsequent acylation or sulfonylation is advantageously carried out with a corresponding halide, anhydride or isocyanate in a solvent such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile or sulfolane, if appropriate in the presence of an inorganic or organic base at temperatures between - 20 and 200 ° C, but preferably at temperatures between -10 and 160 ° C.
  • a solvent such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile or sulfolane, if appropriate in the presence of an inorganic or organic base at temperatures between - 20 and 200 ° C, but preferably at temperatures between -10 and 160 ° C.
  • Triphenylphosphine / carbon tetrachloride at temperatures between -20 and 200 ° C, but preferably at temperatures between -10 and 160 ° C.
  • the subsequent esterification is optionally carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane or particularly advantageously in a corresponding alcohol, optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, e.g.
  • a solvent or solvent mixture such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane or particularly advantageously in a corresponding alcohol, optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, e.g.
  • N, N'-carbonyldiimidazole or triphenylphosphine / carbon tetrachloride expediently carried out at temperatures between 0 and 150 ° C., preferably at temperatures between 0 and 80 ° C.
  • the subsequent alkylation is optionally carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran, dioxane, dimethyl sulfoxide or sulfolane with an alkylating agent such as a corresponding halide or sulfonic acid ester, e.g.
  • a solvent or solvent mixture such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran, dioxane, dimethyl sulfoxide or sulfolane
  • an alkylating agent such as a corresponding halide or sulfonic acid ester, e.g.
  • methyl iodide ethyl bromide, dimethyl sulfate or benzyl chloride
  • a tertiary organic base preferably at temperatures between 0 and 100 ° C.
  • the subsequent reductive alkylation is carried out with a corresponding carbonyl compound such as formaldehyde, acetaldehyde, propionaldehyde, acetone or butyraldehyde in the presence of a complex metal hydride such as sodium borohydride, lithium borohydride or Sodium cyanoborohydride is advantageously carried out at a pH of 6-7 and at room temperature or in the presence of a hydrogenation catalyst, for example with hydrogen in the presence of palladium / carbon, at a hydrogen pressure of 1 to 5 bar.
  • the methylation is preferably carried out in the presence of formic acid as a reducing agent at elevated temperatures, for example at temperatures between 60 and 120 ° C.
  • the subsequent amidation is carried out by reacting a corresponding reactive carboxylic acid derivative with a corresponding amine, if appropriate in a solvent or solvent mixture such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, glacial acetic acid, benzene / tetrahydrofuran or dioxane, the amine used can simultaneously serve as a solvent , optionally in the presence of a tertiary organic base or in the presence of an inorganic base or with a corresponding carboxylic acid in the presence of a dehydrating agent, for example in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, O- (benzotriazol-l-yl
  • the subsequent oxidation is preferably carried out in a solvent or solvent mixture, e.g. in water, water / pyridine, acetone, methylene chloride, acetic acid, acetic acid / acetic anhydride, dilute sulfuric acid or trifluoroacetic acid, depending on the oxidizing agent used, advantageously at temperatures between -80 and 100 ° C.
  • a solvent or solvent mixture e.g. in water, water / pyridine, acetone, methylene chloride, acetic acid, acetic acid / acetic anhydride, dilute sulfuric acid or trifluoroacetic acid, depending on the oxidizing agent used, advantageously at temperatures between -80 and 100 ° C.
  • the oxidation is advantageously carried out with an equivalent of the oxidizing agent used, for example with hydrogen peroxide in glacial acetic acid, trifluoroacetic acid or formic acid at 0 to 20 ° C.
  • a peracid such as Performic acid in Glacial acetic acid or trifluoroacetic acid at 0 to 50 ° C or with m-chloroperbenzoic acid in methylene chloride, chloroform or dioxane at -20 to 80 ° C, with sodium metaperiodate in aqueous methanol or ethanol at -15 to 25 ° C, with bromine in glacial acetic acid or aqueous acetic acid if necessary in the presence of a weak base such as sodium acetate, with N-bromosuccinimide in ethanol, with tert-butyl hypochlorite in methanol at -80 to -30 ° C, with iodobenzodichloride in aqueous pyridine at 0 to 50 ° C, with nitric acid in glacial acetic acid at 0 to 20 ° C, with chromic acid in glacial acetic acid or
  • a peracid such as Performic acid in Glacial
  • the oxidation is advantageously carried out with a corresponding sulfinyl compound using one or more equivalents of the oxidizing agent used or, starting from a corresponding sulfenyl compound, advantageously with two or more equivalents of the oxidizing agent used, e.g. with hydrogen peroxide in glacial acetic acid / -
  • a peracid such as performic acid or m-chloroperbenzoic acid in glacial acetic acid, trifluoroacetic acid, methylene chloride or chloroform at temperatures between 0 and 60 ° C, with nitric acid in glacial acetic acid at 0 to 20 ° C, with chromic acid, sodium periodate or potassium per
  • a mixture of a corresponding sulfinyl and sulfonyl compound of the general formula I which may be obtained in this way is, if desired, subsequently separated by known methods, for example by means of chromatography.
  • a compound of general formula I which contains a tetrazole group is preferably carried out in a solvent such as benzene, toluene or dimethylformamide at temperatures between 80 and 150 ° C, preferably at 120 and 130 ° C.
  • a solvent such as benzene, toluene or dimethylformamide
  • the required hydrochloric acid is expediently obtained from an alkali azide, e.g. out
  • reaction can also be carried out with another salt or derivative of hydrochloric acid, preferably with aluminum azide or tributyltin azide, in which case the any tetrazole compound thus obtained is released from the salt contained in the reaction mixture by acidification with a dilute acid such as 2N hydrochloric acid or 2N sulfuric acid.
  • Hydroxyalkyl group contains, in a corresponding haloalkyl compound is preferably carried out with a halogen-introducing agent such as phosphorus oxychloride or thionyl chloride in a solvent such as methylene chloride at temperatures between 0 and the boiling point of the reaction mixture.
  • a halogen-introducing agent such as phosphorus oxychloride or thionyl chloride in a solvent such as methylene chloride
  • the subsequent conversion of a compound of the general formula I which contains a haloalkyl group into a corresponding aminoalkyl compound of the general formula I is preferably carried out in a solvent such as methylene chloride or acetonitrile or in an excess of the amine used as solvent and optionally in the presence of a tertiary organic base Temperatures between 0 and 150 ° C, preferably at temperatures between 20 and 80 ° C.
  • Triphenylphosphine / azodicarboxylic acid ethyl ester at temperatures between 0 and 50 ° C, preferably at temperatures between 0 and 150 ° C.
  • Contains amino group in a corresponding 1-pyrrolo compound of general formula I is preferably carried out in a solvent such as glacial acetic acid with 2,5-dimethoxy-tetrahydrofuran at temperatures between 20 and 150 ° C, preferably at temperatures between 100 and 150 ° C.
  • a solvent such as glacial acetic acid with 2,5-dimethoxy-tetrahydrofuran at temperatures between 20 and 150 ° C, preferably at temperatures between 100 and 150 ° C.
  • any reactive groups present such as hydroxyl, carboxy, amino, alkylamino or imino groups, can be removed during the Implementation are protected by usual protective groups, which are split off after the implementation.
  • the trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert-butyl, trityl, benzyl or tetrahydropyranyl group comes as a protective radical for a hydroxyl group
  • an amino, alkylamino or imino group the formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and for the amino group additionally Consider phthalyl group.
  • the subsequent subsequent splitting off of a protective residue used takes place, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as sodium hydroxide or potassium hydroxide or aprotic, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.
  • an aqueous solvent e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water
  • an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid
  • an alkali base
  • a benzyl, methoxybenzyl or benzyloxycarbonyl radical is cleaved off, for example, by hydrogenolysis, e.g. with hydrogen in the presence of a catalyst such as palladium / carbon in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 ° C., but preferably at temperatures between 20 and 60 ° C. , and at a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar.
  • a 2,4-dimethoxybenzyl radical is preferably cleaved in trifluoroacetic acid in the presence of anisole.
  • the splitting off of a tert. -Butyl or tert-butyloxycarbonyl radical is preferably carried out by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by Treatment with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or diethyl ether.
  • an acid such as trifluoroacetic acid or hydrochloric acid
  • iodotrimethylsilane optionally using a solvent such as methylene chloride, dioxane, methanol or diethyl ether.
  • a trifluoroacetyl radical is preferably split off by treatment with an acid such as hydrochloric acid, if appropriate in the presence of a solvent such as acetic acid at temperatures between 50 and 120 ° C. or by treatment with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 ° C.
  • a phthalyl radical is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene / water or dioxane at temperatures between 20 and 50 ° C.
  • the compounds of general formula I obtained can be separated into their enantiomers and / or diastereomers.
  • cis / trans mixtures can be separated into their eis and trans isomers, and compounds with at least one optically active carbon atom can be separated into their enantiomers.
  • the cis / trans mixtures obtained can be chromatographed into their eis and trans isomers, the compounds of general formula I obtained which occur in racemates, according to methods known per se (see Allinger NL and Eliel EL in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) in their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms due to their physicochemical differences according to methods known per se, for example by chromatography and / or fractional crystallization, into their diastereomers, which, if they occur in racemic form, can then be separated into the enantiomers as mentioned above.
  • the enantiomers are separated preferably by column separation on chiral phases or by recrystallization from an optically active solvent or by reaction with a salt or derivative such as an ester or amide with the racemic compound forming optically active substance, in particular acids and their activated derivatives or alcohols, and separating the diastereomeric salt mixture or derivative obtained in this way, for example on the basis of different solubilities, the free antipodes being obtained from the pure diastereomeric salts or derivatives by the action of suitable agents can be released.
  • a salt or derivative such as an ester or amide
  • the racemic compound forming optically active substance in particular acids and their activated derivatives or alcohols
  • optically active acids are, for example, the D and L forms of tartaric acid or dibenzoyl tartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid or quinic acid.
  • Suitable optically active alcohols are, for example, (+) - or (-) - menthol
  • optically active acyl radicals in amides are, for example, (+) - or (-) - menthyloxycarbonyl.
  • the compounds of the formula I obtained can be converted into their salts, in particular for pharmaceutical use into their physiologically tolerable salts with inorganic or organic acids.
  • suitable acids for this purpose are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
  • the new compounds of formula I thus obtained if they contain an acidic group such as a carboxy group, can, if desired, subsequently be converted into their salts with inorganic or organic bases, in particular for their pharmaceutical use into their physiologically tolerable salts.
  • Suitable bases are, for example, sodium hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
  • the compounds of the formula I according to the invention and their physiologically tolerable salts have valuable pharmacological properties, in particular that they inhibit the process of Aß formation in cells or the release of Aß from cells. Said ability was tested according to the test description below. The inhibition of Aß formation was checked using the following test system: Production of a suitable cell line ⁇ -secretase HTS:
  • H4 neuroglioma cells (accession number HTB 148 at the "American Type Culture Collection", Manassas, Virginia, USA) were transfected under standard conditions with the reporter construct pFRLuc (Stratagene), which carries the gene for the luciferase.
  • pFRLuc the reporter construct
  • the encoding soluble Gal4 an individual clone that had the highest luciferase activity was selected.
  • Aß-KKK / Gal4 construct a sequence was generated that contained the N-terminal signal sequence of the APP and the first 55 amino acids of Aß (Shoji et al, 1992), linked to the Gal4 coding sequence (Laughan, A and Gesteland, R Molec.
  • the cell clone obtained as described above was used for the second stable transfection with pcDNA3-Aß-KKK Gal4 or pcDNA3-Aß-KKK-ER and the selection with neomycin was carried out under standard conditions (Sambrook and Maniatis, 1989). Individual neomycin-resistant cell clones were examined for expression of the luciferase. The clones with the highest expression were used for the substance analyzes. All transfections were carried out using the Boehringer Mannheim Fugene transfection system according to the manufacturer's instructions.
  • HTS assay principle The double stable HTS cell line is sown on a 96/384 microtiter plate. If the cells become confluent, they are incubated with the respective test substance for a defined period of time. After incubation, the cell medium is removed and the luciferase enzyme activity is determined exactly according to the manufacturer of the test kit used (SteadyGlo, Promega). The presence of endogenous ⁇ -secretase activity in the H4 cells makes this
  • Gal4 Proteolytically cleaved substrate (Aß-KKK Gal4), whereby the transactivator Gal4 can detach from the membrane and get into the cell nucleus.
  • Gal4 binds to Gal4-D A in the cell nucleus Binding domain of the reporter construct and thus activates the expression of the luciferase.
  • the substrate In the presence of a specific ⁇ -secretase inhibitor, the substrate cannot be cleaved and Gal4 remains, bound to the substrate, on the cell membrane, which leads to a reduction up to complete inhibition in the luciferase activity.
  • DMEM complete medium (10% FCS, 1% glutamine, 1% penicillin / streptomycin) at a dilution of 1: 5.
  • the cells are incubated for 24 to 48 hours (depending on the cell clone and dilution used) at 37 ° C., 5% CO 2 and allowed to grow to 80-90% confluency. Now the test substance is added and incubated overnight (8-16h) at 37 ° C and 5% CO 2 .
  • the 96/384 well plates are equilibrated to room temperature (RT).
  • the kit "Steady-Glo" -Luciferase Assay System (Promega Catalog No. E2520) is used.
  • the Luciferase Assay Reagent is thawed and equilibrated to room temperature or freshly prepared (Luciferase Assay substrate dissolved in Luciferase Assay buffer).
  • the medium is aspirated from the cells. 100 ⁇ l (based on 96 well plates) of fresh complete medium are added per well. 100 ⁇ l (based on 96 well plates) of luciferase assay reagent are added and incubated for 5 min at RT. Now the luminescence For 384 well plates, the pipetted quantities are reduced accordingly.
  • the measured values are set in relation to the control and then determined from several measured values of the IC50.
  • the water phase is then extracted twice more with ethyl acetate.
  • the combined organic phases are dried and concentrated.
  • the residue is separated by chromatography on a silica gel column with cyclohexane ethyl acetate (2: 1).
  • aqueous ammonia 9: 1: 1) (65) 2- (3,4-dichlorophenylamino) -4-methylamino-5 - [(ethoxycarbonylmethyl) aminocarbonylarnino] -pyrirnidine implementation with ethyl isocyanatoacetate, mp: 304 ° C ( 66) 2- (3,4-DicUo ⁇ henylamino) -4-methylamino-5-trifluoroacetylaminopyrimidine, mp: 222 ° C (67) 2- (3,4-DicMorphenylanMno) -4-methyla ⁇ nino-5- (imidazolidin-2 , 4-dion-3-yl) ⁇ yrimidine Prepared from the compound of Example 3 (65) by treatment with sodium methylate in methanol, mp: 301 ° C.
  • reaction mixture is chromatographed on a silica gel column with ethyl acetate methanol / concentrated aqueous ammonia (19: 1: 0.5), yield: 86 mg (30% of theory), mp: 350 ° C.
  • the compounds according to the invention can be administered orally, transdermally, intrathecally, by inhalation or parenterally and are present as active constituents in customary dosage forms, for example in compositions which essentially consist of an inert pharmaceutical carrier and an effective dose of the active ingredient, such as, for example, tablets, Dragees, capsules, wafers, powders, solutions, suspensions, emulsions, syrups, suppositories, transdermal systems etc.
  • An effective dose of Compounds according to the invention are between 1 and 5000, preferably between 10 and 1000, particularly preferably between 10-100 mg / dose in the case of oral use, and between 0.001 and 100, preferably between 0.1 and 10 mg / dose in the case of intravenous or intramuscular use.
  • Solutions which contain 0.01 to 1.0, preferably 0.1 to 0.5% active ingredient are suitable for inhalation.
  • the use of powders is preferred for mhalative application. It is also possible to use the compounds according to the invention as an infusion solution, preferably in a physiological saline or nutrient solution.
  • the compounds according to the invention can be used alone or in combination with other active compounds according to the invention, if appropriate also in combination with other pharmacologically active compounds. Suitable forms of use are, for example, tablets, capsules, suppositories, solutions, juices, emulsions or dispersible powders.
  • Corresponding tablets can be mixed, for example, by mixing the active ingredient (s) with known auxiliaries, for example inert diluents such as calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents to achieve the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • auxiliaries for example inert diluents such as calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents to achieve the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • auxiliaries for example inert diluents
  • coated tablets can be produced by coating cores produced analogously to the tablets with agents commonly used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core can also consist of several layers in order to achieve a depot effect or to avoid incompatibilities.
  • the coated tablet shell can also consist of several layers in order to achieve a depot effect, wherein the auxiliaries mentioned above for the tablets can be used.
  • Juices of the active substances or combinations of active substances according to the invention can additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar and a taste-improving agent, for example flavorings such as vanillin or orange extract.
  • a sweetener such as saccharin, cyclamate, glycerol or sugar
  • a taste-improving agent for example flavorings such as vanillin or orange extract.
  • Injection solutions are made in the usual way, e.g. with the addition of preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts
  • Ethylene diamine tetraacetic acid is produced and filled into injection bottles or ampoules.
  • the capsules containing one or more active ingredients or combinations of active ingredients can be produced, for example, by mixing the active ingredients with inert carriers, such as milk sugar or sorbitol, and encapsulating them in gelatin capsules.
  • inert carriers such as milk sugar or sorbitol
  • Suitable suppositories can be produced, for example, by mixing them with carrier agents such as neutral fats or polyethylene glycol or its derivatives.
  • a therapeutically effective daily dose is between 1 and 5000 mg, preferably 100-1000 mg per adult.
  • the finely ground active ingredient, milk sugar and part of the corn starch are mixed together.
  • the mixture is sieved, whereupon it is moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
  • the granules, the rest of the corn starch and the magnesium stearate are sieved and mixed together.
  • the mixture is pressed into tablets of suitable shape and size.
  • the finely ground active ingredient, part of the corn starch, milk sugar, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is sieved and processed with the rest of the corn starch and water to form a granulate which is dried and sieved.
  • the sodium carboxymethyl starch and the magnesium stearate are added, the mixture is mixed and pressed into tablets of a suitable size.
  • the active ingredient, corn starch, milk sugar and polyvinylpyrrolidone are mixed well and moistened with water.
  • the moist mass is pressed through a sieve with a 1 mm mesh size, dried at approx. 45 ° C and then the granules are passed through the same sieve. After admixing magnesium stearate, domed dragee cores with a
  • the dragee cores thus produced are coated in a known manner with a layer consisting essentially of sugar and talc.
  • the finished coated tablets are polished with wax.
  • the substance and corn starch are mixed and moistened with water.
  • the moist mass is sieved and dried.
  • the dry granules are sieved and mixed with magnesium stearate.
  • the final mixture is filled into size 1 hard gelatin capsules.
  • the active ingredient is dissolved in water at its own pH or, if appropriate, at pH 5.5 to 6.5, and sodium chloride as the isotonic agent is added, the solution obtained is filtered pyrogen-free and the filtrate is filled into ampoules under aseptic conditions, which are then sterilized and sealed ,
  • the ampoules contain 5 mg, 25 mg and 50 mg of active ingredient.
  • the hard fat is melted.
  • the milled active substance is homogeneously dispersed at 40 ° C. It is cooled to 38 ° C and poured into weakly pre-cooled suppository molds.

Abstract

L'invention concerne des pyrimidines substituées de formule (I) dans laquelle Ra à Re sont définis comme dans la revendication 1, s'utilisant pour traiter des maladies dans lesquelles des modulateurs de β-amyloïde manifestent une utilité thérapeutique. L'invention concerne en outre leur utilisation pour produire un médicament présentant les propriétés précitées et des méthodes permettant de les utiliser.
EP02772368A 2001-10-17 2002-10-10 Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament Withdrawn EP1453516A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33012801P 2001-10-17 2001-10-17
US330128P 2001-10-17
PCT/EP2002/011345 WO2003032994A2 (fr) 2001-10-17 2002-10-10 Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament

Publications (1)

Publication Number Publication Date
EP1453516A2 true EP1453516A2 (fr) 2004-09-08

Family

ID=23288430

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02772368A Withdrawn EP1453516A2 (fr) 2001-10-17 2002-10-10 Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament

Country Status (3)

Country Link
US (2) US20030134838A1 (fr)
EP (1) EP1453516A2 (fr)
WO (1) WO2003032994A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
CA2451128A1 (fr) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company Inhibiteurs n-heterocycliques d'expression tnf-alpha
PT1438053E (pt) * 2001-10-17 2008-09-25 Boehringer Ingelheim Int Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) * 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
RS20050363A (en) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2529611C (fr) * 2002-12-20 2009-12-15 Pfizer Products Inc. Derives de pyrimidine destines au traitement de la croissance cellulaire anormale
WO2005003103A2 (fr) * 2003-06-30 2005-01-13 Astrazeneca Ab Nouveaux heterocycles 2,4,6-trisubstitues et utilisations de ceux-ci
WO2005016893A2 (fr) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
MX2007002208A (es) 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
DK2354126T3 (da) * 2005-01-14 2014-01-13 Chemocentryx Inc Heteroarylsulfonamider og ccr2
RU2416616C2 (ru) 2005-01-19 2011-04-20 Райджел Фармасьютикалз, Инк. Пролекарства соединений 2,4-пиримидиндиамина и их применения
WO2006101977A2 (fr) * 2005-03-16 2006-09-28 Targegen, Inc. Composes de pyrimidine et methodes d'utilisation
EP1866034A1 (fr) * 2005-03-30 2007-12-19 Boehringer Ingelheim International GmbH 1,2-éthylènediamines substituées, médicaments comprenant lesdits composés ; applications et méthode de fabrication desdits composés et médicaments
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (fr) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
MX2007008848A (es) * 2005-06-08 2008-04-16 Targegen Inc Metodos y composiciones para el tratamiento de desordenes oculares.
CA2617294A1 (fr) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Ethane-1,2-diamines substitues pour le traitement de la maladie d'alzheimer ii
WO2007017509A1 (fr) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Composes pour le traitement de la maladie d'alzheimer
WO2007017510A2 (fr) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Diamides d'acide isophtalique pour le traitement de la maladie d'alzheimer
CA2618481A1 (fr) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Composes utilises pour traiter la maladie d'alzheimer
JP2009504611A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用β−セクレターゼインヒビター
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
RU2597364C2 (ru) * 2005-11-01 2016-09-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
CA2642229C (fr) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions et methodes destinees a l'inhibition de la voie jak
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
ES2863798T3 (es) 2006-03-27 2021-10-11 Univ California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
RU2449993C2 (ru) * 2006-03-29 2012-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилтиогидантоиновые соединения
WO2007146977A1 (fr) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkylèneaminopyrimidines
AU2007257650A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
WO2008008234A1 (fr) 2006-07-07 2008-01-17 Targegen, Inc. Inhibiteurs de type 2-amino-5-substituant-pyrimidines
US8148391B2 (en) * 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
PT2175859E (pt) 2007-07-12 2012-06-06 Chemocentryx Inc Heteroarilpiridil- e fenil-benzenossulfonamidas condensadas como moduladores de ccr2 para o tratamento de inflamação
CA2703635C (fr) 2007-10-26 2017-06-27 Michael E. Jung Composes de diarylhydantoine en tant que modulateurs des recepteurs androgenes
EP2231620A1 (fr) * 2007-12-03 2010-09-29 Boehringer Ingelheim International GmbH Nouveaux composés
JP5328816B2 (ja) * 2008-02-22 2013-10-30 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβの調節薬
US8685972B2 (en) * 2008-08-13 2014-04-01 Merck Sharp & Dohme Corp. Pyrimidine derivatives for treatment of alzheimer's disease
US20100137313A1 (en) * 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
KR101753826B1 (ko) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
KR101740076B1 (ko) * 2009-07-28 2017-06-08 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
WO2011032656A1 (fr) * 2009-09-18 2011-03-24 Bayer Cropscience Ag Dérivés de pyrimidine à substitution 5-fluor-3-thio
EP3124481B1 (fr) 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Modulateurs de récepteur d'androgène et utilisations associées
EP3075730B1 (fr) 2010-06-04 2018-10-24 Genentech, Inc. Dérivés d'aminopyrimidine comme modulateurs lrrk2
WO2012060847A1 (fr) 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procédés de traitement de la myélofibrose
HUE037844T2 (hu) 2010-11-10 2018-09-28 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
KR20210013342A (ko) 2012-09-26 2021-02-03 아라곤 파마슈티컬스, 인코포레이티드 비전이성 거세 저항성 전립선암 치료용 항안드로겐
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN109153650A (zh) * 2016-04-15 2019-01-04 Epizyme股份有限公司 作为ehmt1和ehmt2抑制剂的胺取代的芳基或杂芳基化合物
RU2765737C2 (ru) 2016-11-23 2022-02-02 Хемоцентрикс, Инк. Способ лечения фокально-сегментарного гломерулосклероза
JP2020517618A (ja) 2017-04-21 2020-06-18 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤との併用療法
MX2020003502A (es) 2017-10-11 2021-09-30 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2.
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
AU2020274011B2 (en) 2019-05-10 2024-02-15 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3966207B1 (fr) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phénylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
AU2020297422B2 (en) 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JPH03127790A (ja) * 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
DE4029650A1 (de) * 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
DE69909756D1 (de) 1998-02-17 2003-08-28 Tularik Inc Antivirale pyrimidinderivate
SK287996B6 (sk) 1998-03-27 2012-09-03 Janssen Pharmaceutica N. V. Pyrimide compound, pharmaceutical composition the compound is comprised, method for preparation thereof, combination and product containing the composition and use of the pyrimide compound
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
JP2002523498A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
DE19851421A1 (de) 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma Neue Pyrimidine, deren Herstellung und Verwendung
AP1683A (en) 1998-11-10 2006-11-29 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines.
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
AP2002002479A0 (en) * 1999-09-15 2002-06-30 Warner Lambert Co Pteridinones as kinase inhibitors.
AU767558B2 (en) 1999-09-16 2003-11-13 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogenous six-membered ring compounds
US7087597B1 (en) * 1999-10-12 2006-08-08 Takeda Pharmaceutical Company Limited Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof
JP2003520266A (ja) * 2000-01-24 2003-07-02 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害薬
JP2003523358A (ja) * 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6753410B2 (en) * 2000-03-02 2004-06-22 Merck & Co., Inc. Investigational compounds
US6713248B2 (en) * 2000-04-03 2004-03-30 Bristol-Myers Squibb Company Methods for detection of gamma-secretase activity and identification of inhibitors thereof
US7220736B2 (en) * 2000-04-28 2007-05-22 Tanabe Seiyaku Co., Ltd. Pyrimidine compounds
GB0016681D0 (en) * 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
MXPA03007395A (es) * 2001-02-20 2003-12-04 Bristol Myers Squibb Co Derivados de pirimidin-5-carboxamida 2,4-disustituida como moduladores del canal de potasio kcnq.
BR0208265A (pt) * 2001-03-22 2004-03-02 Bristol Myers Squibb Co Redução estereosseletiva de acetofenona substituìda
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
HUP0600673A3 (en) * 2001-08-03 2011-08-29 Schering Corp Tetrahydroquinolin derivatives as gamma secretase inhibitors nad pharmaceutical compositions containing them
GB0223038D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03032994A3 *

Also Published As

Publication number Publication date
US20050090486A1 (en) 2005-04-28
WO2003032994A2 (fr) 2003-04-24
WO2003032994A3 (fr) 2003-06-12
US7166599B2 (en) 2007-01-23
US20030134838A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
WO2003032994A2 (fr) Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
EP2090571B1 (fr) Derivés pyrimidine, agent pharamceutique contenant ces composés, utilisation et procédé de fabrication de ces composés
DE69830403T2 (de) Inhibitoren des faktors xa mit einer neutralen gruppe mit p1-spezifität
DE60309739T2 (de) Pyridinderivate als modulatoren des cb2-rezeptors
DE60025243T2 (de) Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
EP0129128B1 (fr) Dérivés de 2-pyrimidinyl 1-pipérazine, procédé pour leur préparation et médicaments les contenant
EP1902037B1 (fr) 2,4-diamino-pyrimidines comme inhibiteurs d'aurora
EP2027107B1 (fr) 2, 4 -diamino pyrimidine en tant qu'inhibiteurs de kinases du cycle cellulaire
EP3164509B1 (fr) Inhibiteurs de la déméthylase 1 spécifique de la lysine
DE602004010829T2 (de) Adamantan- und azabicyclooctan- und -nonanderivate, verfahren zu deren herstellung und deren verwendung als dpp-iv-inhibitoren
WO2005113515A1 (fr) Pyrimidines comme inhibiteurs de plk
WO2003020722A1 (fr) Nouvelles dihydropteridinones, procedes pour les produire et leur utilisation en tant que medicaments
HUE026671T2 (en) Heterocyclic derivatives as microsomal prostaglandin E synthetase inhibitors (mPGEs)
EP0772603A1 (fr) Composes substitues de pyrimidine et leur utilisation
EP1781640A1 (fr) Dérivés de 2,4-di(aminophényl)pyrimidine comme inhibiteurs de plk
EP1228060A1 (fr) Arylalcane, arylalcene et aryl-aza-alcane, medicaments renfermant ces composes et leur procede de preparation
EP1530574A1 (fr) Pyrimidines macrocycliques, leur production et leur utilisation comme medicament
CZ200036A3 (cs) Triazolové sloučeniny a jejich použití
DE60303441T2 (de) N-biphenylmethylaminocycloalkancarboxamid-derivative
EP1943227A1 (fr) Nouveaux agonistes beta, leur procede de fabrication et leur utilisation en tant que medicaments
EP3821947A1 (fr) Agonistes heterocycliques de trpml1
WO2007081901A2 (fr) Derives de pyrimidinone comme inhibiteurs de proteines kinases
Albratty et al. Synthesis and antitumor activity of some novel thiophene, pyrimidine, coumarin, pyrazole and pyridine derivatives
EP1341760A1 (fr) 3-(aminomethylidene)-2-indolinones sulfonylamino-substituees comme inhibiteurs de proliferation cellulaire
DE602004000158T2 (de) Triazole für die Behandlung von auf die Modulation des Dopamin D3 Rezeptors ansprechende Krankheiten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040517

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100430